Dr Martens PLC (LSE:DOCS) said sales recovered strongly in its latest quarter as all its stores in the US, US and Europe reopened or started to.
Revenues rose to £147mln in the three months to end June, up 52% year-on-year and by 31% compared with trading pre- the pandemic.
Supply issues are the one cloud on the horizon and becoming a problem said the iconic bootmaker, though it still expects profits this year to hit forecasts.
Over the past three months, retail sales recovered while online continued to power ahead, though it was America that stood out it said with revenues there up by 106%.
Ecommerce sales generally were up by 11% overall, but that compared to a very strong period as lockdowns started around the world.
Dr Martens cautioned though against projecting the first-quarter growth to the rest of the year.
“Trading in Q1 was slightly ahead of our expectations, with a strong end to the period. Q1 is by far the smallest quarter however, and in Q2 we face a much stronger comparative.
“We anticipate that the pattern of trading through the year will be non-linear and, like many others across the industry, we are experiencing inbound shipping delays and other operational challenges due to Covid-19.
“Despite these, we remain confident in the delivery of our guidance for FY22 and over the medium-term.”